Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY: PFE )

26.02 +0.12 (+0.46%)
Streaming Delayed Price Updated: 9:47 AM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years. 
Via The Motley Fool
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient passed away from cardiac arrest after receiving Pfizer's experimental gene therapy for Duchenne muscular dystrophy. Pfizer investigates while trials continue, including Phase 3 study.... 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Check out these healthcare stocks for some healthy payouts. 
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Pfizer Unusual Options Activity
Via Benzinga
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
The pharma-giant's shares could be poised for a trend reversal. 
Via The Motley Fool
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggested strategies to navigate the challenging period. 
Via Benzinga
Topics Economy
Exposures Economy
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Tuesday Talk: Still Flying
The stock market is still on the upswing. For all the anti-Fed pundits, the market seems to be going with Chairman Powell for now. 
Via Talk Markets
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
How this baseball All-Star steps up to the plate when it comes to pneumococcal pneumonia
(BPT) - Professional baseball player JD Martinez is at increased risk for pneumococcal pneumonia because he has asthma, and he doesn't want to let it stop him from taking his shot on - or off - the... 
Via Brandpoint
Revive Your Portfolio: 3 Undervalued Stocks Poised for Growth
While big splashes of red ink represent danger, for contrarian investors, these undervalued growth stocks may spell opportunity. 
Via InvestorPlace
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
These highly advantaged businesses have what they need to keep raising their dividend payouts. 
Via The Motley Fool
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market
Defensive stocks are increasingly safe to buy and attractive as volatility rises and indices fall at large, making time tested shares hot. 
Via InvestorPlace
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
Sometimes the best way to invest your money is in the companies no one is bullish about, just like these three contrarian stocks to buy. 
Via InvestorPlace
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat? 
Via Investor's Business Daily
My Top 5 Favorite High-Yield Dividend Stocks to Buy in May
Income investors can buy in May and go away with these stocks. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.